logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

SABCS 2019 – HER2+ breast cancer: trastuzumab deruxtecan shines in DESTINY trial

Achieves 15-month duration of response but deaths from interstitial lung disease remain a concern.